Quantitative detection of macular microvascular abnormalities identified by optical coherence tomography angiography in different hematological diseases.
Humans
Tomography, Optical Coherence
/ methods
Male
Female
Hematologic Diseases
/ diagnostic imaging
Middle Aged
Retinal Vessels
/ diagnostic imaging
Adult
Fluorescein Angiography
/ methods
Macula Lutea
/ diagnostic imaging
Microvessels
/ diagnostic imaging
Aged
Retinal Diseases
/ diagnostic imaging
Erythrocyte diseases
Lymphocyte diseases
Myelocyte diseases
Optical coherence tomography angiography
Pancytopenia diseases
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
16
06
2024
accepted:
16
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
It is now understood that hematological diseases can have detrimental effects on the retina, reducing retinal capillaries, compromising visual function, and potentially causing irreversible visual impairment. Over the years, there has been limited research on macular microvascular abnormalities, such as changes in vessel density and the foveal avascular zone (FAZ) and variations in the severity of these effects across different types of blood disorders. This study aims to quantitatively assess the impact of various hematological disorders on the retina using optical coherence tomography angiography (OCTA). Compared with healthy eyes, patients with different blood diseases exhibited reductions in linear vessel density (LVD), perfusion vessel density (PVD), FAZ area, and FAZ perimeter. Notably, patients with erythrocyte diseases showed more significant abnormalities in LVD and PVD, while patients with lymphocytic diseases demonstrated more pronounced abnormalities in the FAZ area and perimeter. OCTA imaging could potentially reflect changes of the retinal microvascular of patients with hematological diseases and may serve as a valuable tool for distinguishing abnormalities affecting different blood cell lines. This approach offers a novel avenue for assessing, treating, and monitoring blood disorders.
Identifiants
pubmed: 39455721
doi: 10.1038/s41598-024-76753-8
pii: 10.1038/s41598-024-76753-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25433Subventions
Organisme : Natural Science Foundation for Young Scholars of Shandong Province of China
ID : ZR202111120236
Organisme : Shandong Province "Double-Hundred Talent Plan" on 100 Foreign Experts and 100 Foreign Expert Teams Introduction (For Team)
ID : WST2021004
Organisme : Youth Fund of the National Natural Science Foundation of China
ID : nos.81300383
Organisme : Novo Nordisk Haemophilia Research Fund (NNHRF) China Clinical Research Center of Shandong University
ID : nos. 2020SDUCRCC015
Organisme : Shandong Provincial People's Government, Mount Taishan Scholar Young Expert
ID : tsqn202103167
Informations de copyright
© 2024. The Author(s).
Références
Hemminki, K., Huang, W., Sundquist, J., Sundquist, K. & Ji, J. Autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence. Semin Cancer Biol. Aug. 64, 114–121 (2020).
doi: 10.1016/j.semcancer.2019.06.005
Xu, L. et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology. J. Hematol. Oncol. Mar. 2 (1), 33 (2018).
doi: 10.1186/s13045-018-0564-x
Tomasik, J. & Basak, G. W. Inflammasomes-New contributors to Blood diseases. Int. J. Mol. Sci. Jul 23 ;23(15). (2022).
Hu, D. et al. Cellular senescence and hematological malignancies: from pathogenesis to therapeutics. Pharmacol. Ther. Jul. 223, 107817 (2021).
doi: 10.1016/j.pharmthera.2021.107817
Zhao, E. J., Cheng, C. V., Mattman, A. & Chen, L. Y. C. Polyclonal hypergammaglobulinaemia: assessment, clinical interpretation, and management. Lancet Haematol. May. 8 (5), e365–e375 (2021).
doi: 10.1016/S2352-3026(21)00056-9
Weiss, G., Ganz, T. & Goodnough, L. T. Anemia of inflammation. Blood Jan. 3 (1), 40–50 (2019).
doi: 10.1182/blood-2018-06-856500
Stauder, R., Valent, P. & Theurl, I. Anemia at older age: etiologies, clinical implications, and management. Blood Feb. 1 (5), 505–514 (2018).
doi: 10.1182/blood-2017-07-746446
Zarrabian, D. & Hanna, M. Characterization of pediatric transfusion-dependent thalassemia patients in a large academic center. J. Clin. Lab. Anal. Sep.4, e24962 (2023).
doi: 10.1002/jcla.24962
Viana, M. B., Oliveira, E. L. & Belisario, A. R. Severe clinical picture in a cohort of six Brazilian children with hemoglobin sbeta-thalassemia IVS-I-5 G > A. Blood Cells Mol. Dis. Aug. 30, 104:102795 (2023).
Okayama, Y. et al. The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A. Blood Coagul Fibrinolysis Sep. 1 (6), 419–422 (2023).
doi: 10.1097/MBC.0000000000001243
Pipe, S. W., Dunn, A. L. & Young, G. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia a and B with inhibitors. Expert Rev. Hematol. Aug 21 (2023).
Matarraz, S. et al. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study. Blood Cancer J. Sep. 4 (1), 132 (2023).
doi: 10.1038/s41408-023-00909-4
Awada, H. et al. Gemtuzumab ozogamicin plus standard induction hemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia. Blood Cancer J. Sep. 4 (1), 131 (2023).
doi: 10.1038/s41408-023-00910-x
Ferreri, A. J. M. et al. Burden of illness in follicular lymphoma with multiple lines of treatment, Italian RWE Analysis. Cancers (Basel) Sep. 2 ;15(17). (2023).
Haebe, S. E. et al. Follicular lymphoma evolves with a surmountable dependency on acquired glycosylation motifs in the B cell receptor. Blood. Sep 8. (2023).
Gaudio, A. et al. Hematological diseases and osteoporosis. Int. J. Mol. Sci. May 16 ;21(10). (2020).
Zekavat, S. M. et al. Deep learning of the retina enables phenome- and genome-wide analyses of the microvasculature. Circulation Jan. 11 (2), 134–150 (2022).
doi: 10.1161/CIRCULATIONAHA.121.057709
Garcia-Castineiras, S. Iron, the retina and the lens: a focused review. Exp. Eye Res. Jun. 90 (6), 664–678 (2010).
doi: 10.1016/j.exer.2010.03.003
Mitani, A. et al. Detection of anaemia from retinal fundus images via deep learning. Nat. Biomed. Eng. Jan. 4 (1), 18–27 (2020).
doi: 10.1038/s41551-019-0487-z
Xiao, W. et al. Screening and identifying hepatobiliary diseases through deep learning using ocular images: a prospective, multicentre study. Lancet Digit. Health Feb. 3 (2), e88–e97 (2021).
doi: 10.1016/S2589-7500(20)30288-0
Venkatesh, R. et al. Choroidal and retinal thickness variations in anaemia and anaemic retinopathy. Clin. Exp. Optom. Aug. 105 (6), 602–608 (2022).
doi: 10.1080/08164622.2021.1958653
Benjamini, E., Shimizu, M., Young, J. D. & Leung, C. Y. Immunochemical studies on the tobacco mosaic virus protein. VII. The binding of octanoylated peptides of the tobacco mosaic virus protein with antibodies to the whole protein. Biochem. Apr. 7 (4), 1261–1264 (1968).
doi: 10.1021/bi00844a002
Chollangi, S., Wang, J., Martin, A., Quinn, J. & Ash, J. D. Preconditioning-induced protection from oxidative injury is mediated by leukemia inhibitory factor receptor (LIFR) and its ligands in the retina. Neurobiol. Dis. Jun. 34 (3), 535–544 (2009).
doi: 10.1016/j.nbd.2009.03.012
Chucair-Elliott, A. J. et al. Leukemia inhibitory factor coordinates the down-regulation of the visual cycle in the retina and retinal-pigmented epithelium. J. Biol. Chem. Jul. 13 (29), 24092–24102 (2012).
doi: 10.1074/jbc.M112.378240
Velo-Garcia, A., Castro, S. G. & Isenberg, D. A. The diagnosis and management of the haematologic manifestations of lupus. J. Autoimmun. Nov. 74, 139–160 (2016).
doi: 10.1016/j.jaut.2016.07.001
Krishnan, A. R. et al. Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation. Nephrol. (Carlton) Feb. 22 (Suppl 1), 28–31 (2017).
doi: 10.1111/nep.12937
Zhao, X. et al. Deep-learning-based Hemoglobin Concentration Prediction and Anemia Screening using Ultra-wide Field Fundus images. Front. Cell. Dev. Biol. 10, 888268 (2022).
doi: 10.3389/fcell.2022.888268
pubmed: 35663399
pmcid: 9160874
Duzgun, E., Demir, N., Alkan, A. A., Uslu Dogan, C. & Cakir, A. Retinochoroidal vascular plexuses in patients with iron deficiency anaemia. Clin. Exp. Optom. Apr. 105 (3), 326–332 (2022).
doi: 10.1080/08164622.2021.1916387
Wu, Y. et al. Optical coherence tomography angiography for the characterisation of retinal microvasculature alterations in pregnant patients with anaemia: a nested case–control study. Br. J. Ophthalmol. Nov 25 (2022).
Han, I. C., Tadarati, M. & Scott, A. W. Macular Vascular Abnormalities identified by Optical Coherence Tomographic Angiography in patients with Sickle Cell Disease. JAMA Ophthalmol. Nov. 133 (11), 1337–1340 (2015).
doi: 10.1001/jamaophthalmol.2015.2824
Martin, G. C. et al. Visual function in asymptomatic patients with homozygous sickle cell disease and temporal Macular Atrophy. JAMA Ophthalmol. Oct. 1 (10), 1100–1105 (2017).
doi: 10.1001/jamaophthalmol.2017.3008
Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmol. May. 98 (5 Suppl), 741–756 (1991).
Xu, F. et al. Retinal microvascular signs in pre- and early-stage Diabetic Retinopathy detected using wide-field swept-source Optical Coherence Tomographic Angiography. J. Clin. Med. Jul 26 ;11(15). (2022).
Koca, S. et al. Evaluation of macular and optic disc radial peripapillary vessel density with optical coherence tomography angiography in iron deficiency anemia. Photodiagnosis Photodyn Ther. 38, 102744 (2022).
doi: 10.1016/j.pdpdt.2022.102744
pubmed: 35124273